Bespak expands next-generation nasal offering with launch of NasaDose 

Resyca Announces the Appointment of Deborah Jones as New CEO

Resyca BV successfully recertified for ISO 13485 – valid until 2028

Cyrano Therapeutics and Resyca announce exclusive license agreement for soft mist nasal spray technology for the treatment of persistent smell loss

Resyca receives medical device regulation certificate from TÜV SÜD

Aero Pump and Resyca partner to launch Ultra Soft Nasal Pump Spray, targeting precise nasal drug delivery applications

Silo Pharma and Resyca BV partner on device and CMC development for intranasal PTSD drug SPC-15

Resyca shareholder Bespak announces successful completion of spin-out from Recipharm Group

Recipharm, Medspray and Resyca enter into exclusive licence agreement to develop nasally-delivered drug products using proprietary soft mist technology

Resyca announces leadership changes

Thaerapy BV and Resyca BV announce exclusive licence agreement for Soft Mist Inhaler technology

Stevanato Group collaborates with Resyca ® to develop and manufacture pre-fillable syringes for use in a new soft mist inhaler for the inhalation of sensitive biological products

The potential of nasal sprays for vaccination

Pharmaceutical scientist Imco Sibum about our soft mist inhaler

First pharmaceutical customer on the soft mist inhaler (SMI) platform

Resyca brand and website

Successful clinical trial in COVID with Heparin in Pulmospray

Joint venture Recipharm and Medspray